{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:21:12Z","timestamp":1787473272003,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.prrv.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:11:07Z","timestamp":1776787867000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and extrapulmonary effects of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis following lung transplantation: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"59","author":[{"given":"Laura","family":"Venditto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Neece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0849-874X","authenticated-orcid":false,"given":"Federico","family":"Forgione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Da Pian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore G.","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prrv.2026.04.002_b0005","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jcf.2024.04.006","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with Cystic Fibrosis following liver transplantation: a systematic review","volume":"23","author":"Testa","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.04.002_b0010","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"10.1016\/j.prrv.2026.04.002_b0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2026.04.002_b0020","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/life13071600","article-title":"Lung transplantation in a new era in the field of cystic fibrosis","volume":"13","author":"Huang","year":"2023","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.prrv.2026.04.002_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2024.104236","article-title":"Efficacy of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor on chronic rhinosinusitis in cystic fibrosis","volume":"45","author":"Di Gioia","year":"2024","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"10.1016\/j.prrv.2026.04.002_b0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2024.01.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor\/ivacaftor","volume":"23","author":"Wucherpfennig","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.04.002_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/alr.23557","article-title":"Beyond the Lung. Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on Sinonasal Disease in Children with Cystic Fibrosis","author":"Petitjean","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.prrv.2026.04.002_b0040","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor improves sinonasal outcomes in young children with cystic fibrosis","volume":"2","author":"Stapleton","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"10.1016\/j.prrv.2026.04.002_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70083","article-title":"Improved Clinical Outcomes with Elexacaftor\/Tezacaftor\/Ivacaftor in patients with Cystic Fibrosis and Advanced Lung Disease: Real\u2010World evidence from an Italian Single\u2010Center Study","volume":"13","author":"Perrotta","year":"2025","journal-title":"Pharmacology Res & Perspec"},{"key":"10.1016\/j.prrv.2026.04.002_b0050","article-title":"Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor","volume":"S156919932500075X","author":"Wood","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2026.04.002_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.prrv.2026.04.002_b0060","doi-asserted-by":"crossref","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database of Systematic Reviews and Implementation Reports [Internet]. 2019 Sept 23 [cited 2025 Apr 14];Publish Ahead of Print. Available from: https:\/\/journals.lww.com\/10.11124\/JBISRIR-D-19-00099.","DOI":"10.11124\/JBISRIR-D-19-00099"},{"key":"10.1016\/j.prrv.2026.04.002_b0065","unstructured":"Higgins JPT, Li T, Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from cochrane.org\/handbook."},{"issue":"1","key":"10.1016\/j.prrv.2026.04.002_b0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.prrv.2026.04.002_b0075","series-title":"Stata Statistical Software: Release 18","author":"StataCorp.","year":"2025"},{"issue":"4","key":"10.1016\/j.prrv.2026.04.002_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14007","article-title":"To treat or not to treat: CFTR modulators after lung transplantation","volume":"25","author":"Hayes","year":"2021","journal-title":"Pediatr Transplant"},{"issue":"2","key":"10.1016\/j.prrv.2026.04.002_b0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/alr.22716","article-title":"Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis","volume":"11","author":"Douglas","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"10.1016\/j.prrv.2026.04.002_b0090","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3390\/pharmaceutics15051438","article-title":"Application of physiologically based pharmacokinetic modeling to predict drug\u2013drug interactions between elexacaftor\/tezacaftor\/ivacaftor and tacrolimus in lung transplant recipients","volume":"15","author":"Hong","year":"2023","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.prrv.2026.04.002_b0095","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.prrv.2026.04.002_b0100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2026.04.002_b0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.prrv.2026.04.002_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2025.100210","article-title":"Evaluation of elexacafor\/tezacaftor\/ivacaftor therapy after lung transplantation in cystic fibrosis: the dutch national KOALA study","volume":"7","author":"Van Gemert","year":"2025","journal-title":"JHLT Open"},{"issue":"2","key":"10.1016\/j.prrv.2026.04.002_b0115","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ppul.26217","article-title":"Outcome of elexacaftor\/tezacaftor\/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation","volume":"58","author":"\u00d8rum","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"19","key":"10.1016\/j.prrv.2026.04.002_b0120","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.prrv.2026.04.002_b0125","first-page":"1256","article-title":"Adverse events and drug interactions associated with elexacaftor\/tezacaftor\/ivacaftor treatment: a descriptive study across australian, canadian, and american adverse event databases","volume":"15","author":"Thiruchelvam","year":"2025","journal-title":"Life (Basel)"},{"key":"10.1016\/j.prrv.2026.04.002_b0130","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del Allele: a phase 3, open-label extension study","author":"Daines","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.prrv.2026.04.002_b0135","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1164\/rccm.200903-0425OC","article-title":"Obesity and underweight are associated with an increased risk of death after lung transplantation","volume":"180","author":"Lederer","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.prrv.2026.04.002_b0140","article-title":"Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis","volume":"49","author":"da Silva Filho","year":"2024","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.prrv.2026.04.002_b0145","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio Kaftrio\u202f: EPAR - Risk management plan RMP version 9.2 First published: 21\/08\/2020Last updated: 29\/01\/2025."},{"key":"10.1016\/j.prrv.2026.04.002_b0150","article-title":"Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant","volume":"S1569199325000785","author":"Guimbellot","year":"2025","journal-title":"J Cyst Fibros"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T07:48:55Z","timestamp":1787471335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054226000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S1526054226000266"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2026.04.002","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and extrapulmonary effects of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis following lung transplantation: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}